Critical Limb Ischemia - Drug Pipeline Landscape, 2023
Description
Critical Limb Ischemia - Drug Pipeline Landscape, 2023
Critical limb ischemia is a serious form of peripheral arterial disease, or PAD where severe blockage in the arteries of the lower extremities (hands, feet and legs) occurs, which markedly reduces blood-flow. It results in severe pain and even skin ulcers or sores.
Peripheral artery disease causes chronic limb-threatening ischemia. Other causes of limb ischemia include embolisms, trauma and compartment syndrome.
The most common symptom of critical limb ischemia is ischemic rest pain. Other symptoms include pain or numbness in the feet, shiny, smooth, dry skin of the legs or feet and thickening of the toenails.
Diagnosis methods of critical limb ischemia includes ankle brachial index test, duplex ultrasound scanning, magnetic resonance arteriography (mra), arteriogram, auscultation and CT angiography.
Critical limb ischemia can be treated with medications, endovascular treatments and surgery.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of Critical Limb Ischemia treatment such as NL003, ASCT01, GUR-602, and others. Key players involved in the development of therapies to treat Critical Limb Ischemia are BioGenCell, Cynata Therapeutics, Gurus BioPharma and others. Four drugs are under Phase III clinical trials and nine drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.
Report Highlights
Global Insight Service's, Critical Limb Ischemia - Drug Pipeline Landscape, 2023 report provides an overview of the Critical Limb Ischemia pipeline drugs. This report covers detailed insights on Critical Limb Ischemia drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Critical Limb Ischemia pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Critical limb ischemia is a serious form of peripheral arterial disease, or PAD where severe blockage in the arteries of the lower extremities (hands, feet and legs) occurs, which markedly reduces blood-flow. It results in severe pain and even skin ulcers or sores.
Peripheral artery disease causes chronic limb-threatening ischemia. Other causes of limb ischemia include embolisms, trauma and compartment syndrome.
The most common symptom of critical limb ischemia is ischemic rest pain. Other symptoms include pain or numbness in the feet, shiny, smooth, dry skin of the legs or feet and thickening of the toenails.
Diagnosis methods of critical limb ischemia includes ankle brachial index test, duplex ultrasound scanning, magnetic resonance arteriography (mra), arteriogram, auscultation and CT angiography.
Critical limb ischemia can be treated with medications, endovascular treatments and surgery.
Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of Critical Limb Ischemia treatment such as NL003, ASCT01, GUR-602, and others. Key players involved in the development of therapies to treat Critical Limb Ischemia are BioGenCell, Cynata Therapeutics, Gurus BioPharma and others. Four drugs are under Phase III clinical trials and nine drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.
Report Highlights
Global Insight Service's, Critical Limb Ischemia - Drug Pipeline Landscape, 2023 report provides an overview of the Critical Limb Ischemia pipeline drugs. This report covers detailed insights on Critical Limb Ischemia drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Critical Limb Ischemia pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.
Methodology
The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.
Scope
The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.
Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.
Table of Contents
95 Pages
- 1. Introduction
- 1.1 Critical Limb Ischemia Pipeline Drugs, 2023-Coverage
- 2. Disease Overview - Critical Limb Ischemia
- 2.1 Causes
- 2.2 Signs and Symptoms
- 2.3 Diagnosis
- 2.4 Disease Management
- 3. Critical Limb Ischemia - Pipeline Drugs Development - Overview
- 3.1 Comparative Analysis by Stage of Development
- 3.2 Number of Products under Development by Companies, 2023
- 3.3 Products under Development by Companies, 2023
- 4. Assessment of Therapeutics
- 4.1 Assessment by Target
- 4.2 Assessment by Mechanism of Action
- 4.3 Assessment by Molecule Type
- 4.3 Assessment by Route of Administration
- 5. Drug Profiles
- 5.1 Clinical Stage Drugs-Phase III
- 5.1.1 AMG0001
- 5.1.2 NL003
- 5.1.3 PLX-PAD
- 5.1.4 REX-001
- 5.2 Clinical Stage Drugs-Phase II
- 5.2.1 Allogenic MSC
- 5.2.2 ASCT01
- 5.2.3 BGC101
- 5.2.4 CLBS12
- 5.2.5 SB-030
- 5.2.6 YQ23
- 5.3 Early Stage Drugs-IND/CTA Filed
- 5.3.1 Cymerusâ„¢ MSCs
- 5.4 Early Stage Drugs-Preclinical
- 5.4.1 AMB201
- 5.4.2 ATI-1013
- 5.4.3 GUR-602
- 5.4.4 MSC-VEGF
- 6. Key Regulatory Designations
- 7. Key Deals
- 8. Key Upcoming Milestones
- 9. Key Companies Involved
- 9.1 Ambulero, Inc.
- 9.2 AnGes USA, Inc.
- 9.3 Antidote Therapeutics
- 9.4 Beijing Northland Biotech. Co., Ltd.
- 9.5 BioGenCell Ltd
- 9.6 Caladrius Biosciences, Inc.
- 9.7 Cynata Therapeutics Limited
- 9.8 Gurus BioPharm LLC
- 9.9 Ixaka Ltd
- 9.10 Lifecells, LLC.
- 9.11 New Beta Innovation Limited
- 9.12 Pluristem Ltd.
- 9.13 Symic Bio Inc
- 9.14 Taiwan Bio Therapeutics Co., Ltd.
- 10. Dormant Drugs
- 10.1 Inactive Drugs
- 10.2 Discontinued Drugs
- 11. Appendix
- List of Tables
- Table 1. 2 Number of Products under Development by Companies
- Table 1. 3 Products under Development by Companies
- Table 1. 4 Products by Targets
- Table 1. 5 Products by Mechanism of Action
- Table 1. 6 Products by Molecule Type
- Table 1. 7 Products by Route of Administration
- Table 2. 1 Clinical Trial Details - AMG0001/AnGes USA, Inc.
- Table 2. 2 Clinical Trial Details - NL003/Beijing Northland Biotech. Co., Ltd.
- Table 2. 3 Clinical Trial Details - PLX-PAD/Pluristem Ltd.
- Table 2. 4 Clinical Trial Details - REX-001/Ixaka Ltd
- Table 2. 5 Clinical Trial Details - Allogenic MSC/Taiwan Bio Therapeutics Co., Ltd.
- Table 2. 6 Clinical Trial Details - ASCT01/Lifecells, LLC.
- Table 2. 7 Clinical Trial Details - BGC101/BioGenCell Ltd.
- Table 2. 8 Clinical Trial Details - CLBS12/ Caladrius Biosciences, Inc.
- Table 2. 9 Clinical Trial Details - YQ23/ New Beta Innovation Limited.
- Table 3. 1 Regulatory Designations
- Table 4. 1 Inactive Drugs
- Table 4. 2 Discontinued Drugs
- List of Figures
- Figure 1. 1 Number of Products under Development for Critical Limb Ischemia, 2023
- Figure 1. 2 Products by Top 5 Targets and Stage of Development for Critical Limb Ischemia, 2023
- Figure 1. 3 Products by Top 5 Mechanism of Action and Stage of Development for Critical Limb Ischemia, 2023
- Figure 1. 4 Products by Top 5 Molecule Type and Stage of Development for Critical Limb Ischemia, 2023
- Figure 1. 5 Products by Top 5 Route of Administration and Stage of Development for Critical Limb Ischemia, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
